Private company Delix Therapeutics raises $70 million, focusing on non-hallucinatory candidates to treat brain disorders.
Psychedelics
MINDCURE Launches "Desire Project" To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy
MINDCURE launches "Desire Project", taking a psychotherapy approach to female hypocactive sexual disorder.
MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration
MindMed provides updates on two of its research initiatives, in partnership with the Liechti Lab (Switzerland).
Levitee Labs Announces DTC Eligibility Approval
Levitee Labs announces that its shares are now eligible for clearing through the DTC.
Novamind Announces DTC Eligibility for its Common Shares
Novamind announces that its shares are now eligible for electronic clearing through the DTC.
Are Psychedelic Stocks About To Heat Up (Again)?
Recent market clues are suggesting that a much overdue rally for psychedelic stocks may be about to begin.
Feds Fund Study Into Whether Psilocybin Can Help People Quit Smoking Cigarettes
A top federal drug agency is funding a study into how psilocybin could help people quit smoking cigarettes—one of the latest examples of the government’s growing interest in psychedelic therapy.
Magic Mushrooms May Be the Biggest Advance in Treating Depression Since Prozac
For most of his adult life, Aaron Presley, age 34, felt like a husk of a person, a piece of "garbage."
Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data
Mydecine announces filing of patent application for psilocybin-based MYCO-003. Pre-clinical data is showing MYCO-003 to work better than pure psilocybin.
The Mental Health Crisis and Psychedelics: Big Business Targets The Sector
Psychedelic medicine is the solution to the Mental Health Crisis. Psychedelic drugs are a huge commercial opportunity. Big Business moves in.
Psyched Wellness Initiates a Clinical Sleep Study on Humans for a Structure/Function Claim For AME-1
Psyched Wellness is preparing for a clinical sleep study for its proprietary extract, AME-1.
Former GOP Congresswoman Touts Psilocybin As Treatment For Alcoholism
A former Republican congresswoman is touting the therapeutic benefits of psychedelics, sharing the story of how a close family friend was able to recover from alcoholism with the help of psilocybin.
Small Pharma Successfully Completes Phase I Clinical Trial Of DMT In Combination With Supportive Psychotherapy
Small Pharma shows DMT to be well-tolerated and safe for the study population as it moves forward toward a Phase IIa clinical trial.
Italian Referendum To Decriminalize Marijuana, Psilocybin And Other Drug Plants Gets Half A Million Signatures
Activists in Italy say they’ve gathered enough signatures to qualify a ballot measure that would decriminalize personal cultivation and use of not only marijuana but also psilocybin mushrooms and certain other psychoactive plants for personal use.
The Three Psychedelics ETFs: Which Is The Best Fit For Your Portfolio?
We take a closer look at each of the three psychedelics ETFs and analyze the investment objectives that each ETF addresses.